Pharmacokinetics
The pharmacokinetic profile of Avonex was studied indirectly during trials to measure the antiviral activity of interferon. With intramuscular use of Avonex, peak levels of antiviral activity were achieved in plasma in the period from 5 to 15 hours after dose administration, T1/2 was about 10 hours . Bioavailability of the drug — approximately 40%.
Indications
- treatment of outpatients suffering from relapsing multiple sclerosis, characterized by at least two repeated attacks of neurological dysfunction (relapses) during the previous 3-year period with no evidence of disease progression between relapses;
- Treatment of patients who have had a case of demyelination as a result of an active inflammatory process requiring IV corticosteroids, with the exclusion of a diagnosis other than multiple sclerosis.
